96 related articles for article (PubMed ID: 2990689)
1. Pharmacological inhibition of infectivity of HTLV-III in vitro.
Mitsuya H; Matsushita S; Harper ME; Broder S
Cancer Res; 1985 Sep; 45(9 Suppl):4583s-4587s. PubMed ID: 2990689
[TBL] [Abstract][Full Text] [Related]
2. Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro.
Mitsuya H; Matsushita S; Yarchoan R; Broder S
Princess Takamatsu Symp; 1984; 15():277-88. PubMed ID: 6085846
[TBL] [Abstract][Full Text] [Related]
3. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.
Mitsuya H; Popovic M; Yarchoan R; Matsushita S; Gallo RC; Broder S
Science; 1984 Oct; 226(4671):172-4. PubMed ID: 6091268
[TBL] [Abstract][Full Text] [Related]
4. Implications of the discovery of HTLV-III for the treatment of AIDS.
Yarchoan R; Mitsuya H; Matsushita S; Broder S
Cancer Res; 1985 Sep; 45(9 Suppl):4685s-4688s. PubMed ID: 2410113
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I.
Matsushita S; Mitsuya H; Reitz MS; Broder S
J Clin Invest; 1987 Aug; 80(2):394-400. PubMed ID: 3038956
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus.
Yarchoan R; Redfield RR; Broder S
J Clin Invest; 1986 Aug; 78(2):439-47. PubMed ID: 3016028
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of retroviral DNA polymerase: their implication in the treatment of AIDS.
Chandra P; Vogel A; Gerber T
Cancer Res; 1985 Sep; 45(9 Suppl):4677s-4684s. PubMed ID: 2410112
[TBL] [Abstract][Full Text] [Related]
8. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV).
Balzarini J; Mitsuya H; De Clercq E; Broder S
Int J Cancer; 1986 Mar; 37(3):451-7. PubMed ID: 2419266
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.
Mitsuya H; Broder S
Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1911-5. PubMed ID: 3006077
[TBL] [Abstract][Full Text] [Related]
10. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.
McDougal JS; Mawle A; Cort SP; Nicholson JK; Cross GD; Scheppler-Campbell JA; Hicks D; Sligh J
J Immunol; 1985 Nov; 135(5):3151-62. PubMed ID: 2995487
[TBL] [Abstract][Full Text] [Related]
11. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.
Sodroski J; Goh WC; Rosen C; Campbell K; Haseltine WA
Nature; 1986 Jul 31-Aug 6; 322(6078):470-4. PubMed ID: 3016552
[TBL] [Abstract][Full Text] [Related]
12. Differential response to the cytopathic effects of human T-cell lymphotropic virus type III (HTLV-III) superinfection in T4+ (helper) and T8+ (suppressor) T-cell clones transformed by HTLV-I.
De Rossi A; Franchini G; Aldovini A; Del Mistro A; Chieco-Bianchi L; Gallo RC; Wong-Staal F
Proc Natl Acad Sci U S A; 1986 Jun; 83(12):4297-301. PubMed ID: 2424024
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunological findings in HTLV-III infection.
Krohn KJ; Antonen J; Valle SL; Kazakevicius R; Saxinger C; Gallo RC; Ranki A
Cancer Res; 1985 Sep; 45(9 Suppl):4612s-4615s. PubMed ID: 2990694
[TBL] [Abstract][Full Text] [Related]
14. Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses.
Margolick JB; Volkman DJ; Folks TM; Fauci AS
J Immunol; 1987 Mar; 138(6):1719-23. PubMed ID: 3493285
[TBL] [Abstract][Full Text] [Related]
15. [Acquired immune deficiency syndrome (AIDS)].
Drusin LM; Stingl G
Z Hautkr; 1985 Sep; 60(18):1432-60. PubMed ID: 2998109
[TBL] [Abstract][Full Text] [Related]
16. Prospects for treatment of human retrovirus-associated diseases.
Bolognesi DP; Fischinger PJ
Cancer Res; 1985 Sep; 45(9 Suppl):4700s-4705s. PubMed ID: 2410116
[TBL] [Abstract][Full Text] [Related]
17. Functional modifications of alloreactive T cell clones infected with HTLV-I.
Suciu-Foca N; Rubinstein P; Rohowsky-Kochan C; Cai J; Popovic M; Gallo RC; King DW
J Immunol; 1986 Aug; 137(4):1115-9. PubMed ID: 3016087
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of human T-lymphotropic leukemia virus type III associated with the acquired immunodeficiency syndrome.
Wong-Staal F; Hahn BH; Shaw GM; Arya SK; Harper M; Gonda M; Gilden R; Ratner L; Starcich B; Okamoto T
Princess Takamatsu Symp; 1984; 15():291-300. PubMed ID: 6100646
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro.
Mitsuya H; Broder S
AIDS Res Hum Retroviruses; 1988 Apr; 4(2):107-13. PubMed ID: 2835072
[TBL] [Abstract][Full Text] [Related]
20. Suramin in the treatment of AIDS: mechanism of action.
De Clercq E
Antiviral Res; 1987 Jan; 7(1):1-10. PubMed ID: 2432836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
